No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

ENPICOM Launches Versatile Display Data Analysis Solution to Accelerate Antibody Selection While Maximizing Precision

The new IGX-Track App adds seamless analysis of antibody panning campaigns to the IGX Platform

Editor: What To Know

  • With a diverse team of over 45 experts in various disciplines, ENPICOM serves customers from all over the world, ranging from academic research centers doing basic research related to the immune system, to biotech and global pharmaceutical companies focusing on the discovery and development of novel immunotherapies and vaccines.
  • “Our customer-centric approach to product development gives us a close-up view of the complex analysis workflows required for antibody display screening and how a single, scalable tool can immensely improve speed of analysis and quality of the selected candidates.
  • The new IGX-Track App extends the antibody discovery capabilities of the IGX Platform and provides a fast, flexible way to discover a diverse set of enriched candidates with the best characteristics.

ENPICOM, an innovative bioinformatics software company, announced the upcoming expansion of the capabilities of the IGX Platform to unlock seamless analysis of antibody panning data.

This major development will allow researchers to analyze antibody display data in an intuitive and visual way, easily perform multi-dataset comparisons, and identify a diverse set of enriched candidates with the best characteristics.

“Our customer-centric approach to product development gives us a close-up view of the complex analysis workflows required for antibody display screening and how a single, scalable tool can immensely improve speed of analysis and quality of the selected candidates.” said Jos Lunenberg, co-founder and Chief Executive Officer at ENPICOM. “Due to limited, inefficient workflows researchers often have to discard the vast majority of the available NGS data and focus on a small pool of the most frequent clones. We are launching the new IGX-Track App so that our customers can look beyond the tip of the iceberg and make informed decisions with a complete view of their data. Custom analysis workflows and visualizations can be created with a few clicks so scientists can simply select better antibodies faster.”

Enabling streamlined enrichment analysis

Display technologies empower antibody discovery by screening millions of candidates against potential targets. By including different panning round conditions and a variety of antigens, researchers can obtain a robust candidate pool with diverse binding profiles. However, complex analysis workflows – including operations like intersecting, joining, or subtracting datasets – that match the panning campaign design are needed to fully take advantage of the powerful combination of NGS and display screening.

The new IGX-Track App extends the antibody discovery capabilities of the IGX Platform and provides a fast, flexible way to discover a diverse set of enriched candidates with the best characteristics. Scientists can effortlessly compose enrichment analysis workflows that match the design of their panning campaigns and discover candidates that otherwise would have been overlooked.

Scientists using IGX-Track on the IGX Platform will be able to:

  • Track clones across panning rounds to identify highly enriched candidates through tabular views and interactive, user-defined visualizations.
  • Freely join, intersect, and subtract many datasets to match their panning campaign design.
  • Broaden their analysis beyond just the most frequent clones with the platform’s scalable, NGS-ready architecture.
  • Easily subtract irrelevant antibodies identified in control panning conditions from the candidates enriched on target.
  • Make fully informed choices, while avoiding bias, by overlaying accurate liability predictions, assay data, and more onto enrichment graphs.

The company will launch the new functionality at the Antibody Engineering and Therapeutics conference on June 8 in Amsterdam.

ENPICOM is an innovative bioinformatics software engineering company delivering ground-breaking products and customized solutions to decode the immune system and improve human health. With a diverse team of over 45 experts in various disciplines, ENPICOM serves customers from all over the world, ranging from academic research centers doing basic research related to the immune system, to biotech and global pharmaceutical companies focusing on the discovery and development of novel immunotherapies and vaccines.

Leveraging a unique mix of immunology knowledge, bioinformatics method development, and software engineering skills, ENPICOM offers a world-class repertoire sequencing data analysis solution – the ImmunoGenomiX (IGX) Platform. IGX is an innovative platform to manage, store, analyze, visualize, and interpret immune repertoire sequencing data from T and B cell receptors. Together with its partners, ENPICOM delivers full immune repertoire sequencing and analysis service.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

VeraClinic: Pioneering Personal Transformation Through Hair Transplantation and Cosmetic Surgery in Turkey

As a testament to Turkey's legacy in the world of aesthetic medicine, VeraClinic invites you to discover the transformative power of our hair transplantation and cosmetic surgery services.

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy